β‐adrenergic receptor antagonists, which interfere with proliferative re‐activation norepinephrine (NE) signalling, may reduce cancer relapse or slow disease progression.129 One potential strategy is finding a way to inhibit E‐selectin, which could limit the ability of the cancer cells to travel into the bone and resurge as metastatic cancer. This evidence concerns the gene SELE and cancer.